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Dopaminergic-cholinergic imbalance 
in movement disorders: a role for 
the novel striatal dopamine D2- 
muscarinic acetylcholine M1 receptor 
heteromer
The  st r iatum i s  the  pr imar y  input 
structure of the basal ganglia, which 
participates in motivational and goal-
directed behaviors (Pisani et al., 2007). In 
physiological conditions, local cholinergic 
interneurons (ChIs) and dopaminergic 
afferents modulate basal ganglia output 
through striatal projection neurons, 
a l so  ca l led  medium sp iny  neurons 
(MSNs). In general, the release of the 
neurotransmitters dopamine (DA) and 
acetylcholine (ACh) elicits contradictory 
effects on MSNs, which express their 
corresponding DA receptors (DARs) 
and muscarinic acetylcholine receptors 
(mAChRs) ,  respect ively  (Ztaou and 
Amalric, 2019). Recently, we discovered a 
novel receptor-receptor interaction (i.e., 
heteromerization) between the dopamine 
D2 receptor (D2R) and the muscarinic 
acetylcholine M1 receptor (M1R), both 
expressed at striatopallidal MSNs (Crans 
et al., 2020). The putative striatal D2R-
M1R complex coordinates a sophisticated 
interplay between the dopaminergic 
and chol inergic  neurotransmiss ion 
systems. Fuxe et al. (2012) foresaw that 
the existence of this heteromer within 
the str iatum would mechanist ical ly 
justify the use of anticholinergics in 
Parkinson’s disease (PD) treatment, thus 
opening up the development of novel 
pharmacotherapeutic strategies for PD 
management. As a proof of concept, 
we demonstrated that an M1R-selective 
antagonist (i.e., VU0255035, 10 mg/kg, 
i.p.) potentiated the antiparkinsonian-
like efficacy of an ineffective D2R-selective 
agonist dose (i.e., sumanirole, 3 mg/kg, 
i.p.) in a rodent model of experimental 
Parkinsonism (Crans et al., 2020). Overall, 
the novel D2R-M1R heteromer could serve 
as a specific drug target to alleviate motor 
deficits in PD, whereas it may avoid major 
adverse effects associated with traditional 
pharmacotherapies. 
T h e  d o rs a l  s t r i at u m  i s  i n n e r vate d 
by excitatory thalamic and cort ical 
glutamatergic afferents and nigrostriatal 
DA-projecting neurons, where the latter 
is known to modulate the cortical-basal 
ganglia-thalamic circuit. Importantly, 
GABAergic MSNs are the only striatal 
efferent projections and descend to basal 
ganglia outputs (i.e., globus pallidus 
pars interna and substantia nigra pars 
reticulata) by two pathways, a direct 
(monosynaptic) connection and an indirect 
pathway through the globus pallidus 
pars externa and subthalamic nucleus 
(Figure 1A). While the MSNs of these two 
efferent pathways are anatomically and 
morphologically identical, the expression 
of key genes allows to differentiate 
between them. Thus, the MSNs of the 
direct pathway (i.e., striatonigral neurons) 
contain the neuropeptides substance P 
and dynorphin and express dopamine D1 
receptors (D1Rs), which are coupled to Gs/a 
proteins. In contrast, the MSNs belonging 
to the indirect pathway (i.e., striatopallidal 
neurons) express D2R, coupled to Gi/o 
proteins, adenosine A2A receptor (A2AR) and 
the neuropeptide enkephalin. Activating 
D1R-MSNs or D2R-MSNs results in an 
opposite effect due to the stimulation or 
inhibition of adenylyl cyclase, respectively. 
Nevertheless, the release of striatal DA 
from nigrostriatal DA-projections increases 
thalamo-cortical activity by the direct or 
indirect inhibition of basal ganglia outputs 
and, thus, voluntary motor function (Lester 
et al., 2010). MSNs constitute 90–95% of 
all striatal neurons, while the remaining 
population consists of local ChIs and 
GABAergic interneurons in the striatum. 
Giant, aspiny ChIs only represent 1–3% 
of striatal neurons, although they are 
responsible for the highest concentration 
of ACh in the brain and collude with DA 
inputs to regulate motor function (Ztaou 
and Amalric, 2019). Indeed, more basal 
ganglia nuclei containing ChIs are also 
heavily innervated by dopaminergic 
terminals (i.e., nucleus accumbens and 
olfactory tubercle), which presents a 
similar functional interplay between the 
dopaminergic and cholinergic systems 
(Pisani et al., 2007). In contrast to other 
striatal neurons, ChIs possess an intrinsic 
firing activity in the absence of external 
stimuli. These autonomous pacemakers 
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modulate the activit ies of neuronal 
afferents, but they are primarily targeting 
MSNs through their widely arborizing 
axons and dense terminal fields. The 
ChIs effects are controlled by two types 
of receptors, namely the mAChRs and 
ionotropic  n icot in ic  ACh receptors 
(nAChRs). Five distinct mAChRs subtypes 
(M1R–M5R) have been identified and 
classified based on their pharmacological 
and molecular  character ist ics .  The 
excitatory M1-like receptors (M1R, M3R 
and M5R) transduce their signals through 
Gq/11 proteins, whereas the inhibitory M2-
like receptors (M2R and M4R) are coupled 
to Gi/o proteins. Noteworthy, the D1R-
MSNs express postsynaptic M4R, while 
M1Rs are expressed at both D1R-MSNs and 
D2R-MSNs. The complexity of the striatal 
circuitry is characterized by the variety of 
DARs, mAChRs and nAChRs expression as 
well as their subcellular location at ChIs, 
MSNs, nigrostriatal DA-projecting neurons, 
thalamostr iata l  and cort icostr iata l 
glutamatergic afferents (Figure 1A). 
The disruption of the striatal circuitry 
result in basal ganglia dysfunction causing 
movement disorders, such as PD, dystonia, 
Hunt ington’s  d isease and Tourette 
syndrome (Pisani et al., 2007). PD is the 
second most common neurodegenerative 
disorder and is well-characterized by 
cardinal signs, including bradykinesia, 
muscular rigidity and resting tremors. The 
major PD pathophysiological hallmark 
is the progressive loss of dopaminergic 
afferents from the substantia nigra pars 
compacta, resulting in the reduction 
of striatal DA levels, increase in striatal 
ACh/DA ratio and dysregulation of ChIs 
transmission (McKinley et al., 2019). 
Early clinical studies show that both 
dopaminergic agonist and anticholinergic 
drugs provide a relief in parkinsonian 
rigidity and tremors, which led to the 
DA/ACh balance hypothesis  (Ztaou 
and Amalric, 2019). Anticholinergics 
(e.g., benztropine and biperiden) were 
the main therapeut ic  agents  in  PD 
treatment before the discovery of L-3,4-
dihydroxyphenylalanine (L-DOPA) and 
DAR agonists. Nowadays, their use is 
limited due to severe adverse effects (e.g., 
hallucinations, cognitive impairments, 
dry mouth, urinary retention and blurred 
vision) and only prescribed to relatively 
young patients in the early stages of PD. 
Indeed, DA replacement therapy with 
L-DOPA has been proven to be the “gold 
standard” to effectively manage motor 
deficits. However, long-term L-DOPA 
therapy is limited in most patients by the 
development of abnormal involuntary 
m ove m e nt s  ( i . e . ,  L - D O PA- i n d u c e d 
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dyskinesia). Chronic L-DOPA treatment 
has been shown to enhance basal firing 
and induce stronger excitatory responses 
to DA in striatal ChIs (Ding et al., 2011). 
Overall, while many current dopaminergic 
and anticholinergic based treatments 
target  mul t ip le  DARs  and  mAChRs 
subtypes simultaneously, selective drugs 
targeting D2R and M1R within the striatum 
in a multimodal fashion may improve the 
patient’s quality of life during the course 
of the disease (McCall et al., 2005; Sheffler 
et al., 2009).
Interestingly, G protein-coupled receptor 
ol igomerization has been shown to 
regulate  receptor  pharmacologica l 
responses due to receptor-receptor 
modulation (i.e., allosteric interaction), 
indirect downstream effectors ( i .e., 
canonical interaction) and/or feedback 
control  mechanisms.  Many str iata l 
D2R-containing heteromers have been 
descr ibed prev ious ly,  where in  the 
functionality of the receptor is fine-
tuned through a molecular interaction 
with another endogenously expressed 
G  p ro te i n - co u p l e d  re c e pto r  ( e . g . , 
adenosine, cannabinoid and metabotropic 
glutamate receptors). In literature, the 
heteromerizat ion between D 2R and 
A2AR has been well-characterized within 
the context of PD. Thus, a reciprocal 
antagonistic receptor-receptor interaction 
was demonstrated due to the capability 
of A2AR to tightly control D2R activity and 
vice versa, both at allosteric and canonical 
interaction levels, which play a pivotal role 
to regulate motor function (Ferre et al., 
2018). This functional interplay grounded 
the utility of A2AR blockade to alleviate 
motor deficits, which recently led to the 
approval of an A2AR-selective antagonist, 
istradefylline (Nourianz®), as an adjuvant 
drug in PD treatment. However, while a 
variety of D2R-containing complexes exist, 
only a few heteromers for M1R have been 
described in living cells (Fuxe et al., 2012). 
In our study, we described for the first 
time the existence of D2R-M1R heteromers 
through biophysical and biochemical 
cell-based assays. Subsequently, a co-
distribution between these receptors 
in the mouse striatum was observed by 
double-immunofluorescence labeling. 
Moreover, we detected these D2R-M1R 
complexes with a new AlphaScreen-based 
assay in striatal membranes from wild-
type mice, but not from D2R-deficient mice 
(Crans et al., 2020). The Alpha technology 
has recently been optimized and validated 
by our research group through the 
detection of D2R-A2AR heteromers in 
mice and post-mortem human brains. 
Importantly,  our new AlphaScreen-
based assay showed a high sensitivity, 
robustness and signal-to-background ratio, 
which is suitable to be implemented in 
high-throughput screenings (Fernandez-
Duenas et al., 2019). Furthermore, the 
detection of D2R-A2AR heteromers was not 
influenced by necropsies or the variable 
time and conservation protocols of tissue 
extraction. Hence, the successful detection 
of the novel D2R-M1R interaction in the 
mouse striatum provides an opportunity 
to gain further insights of these complexes 
in healthy controls versus PD patients, 
w h e re a s  o t h e r  re c e p t o r- re c e p t o r 
interaction assays (e.g., proximity ligation 
assay, immuno-electron microscopy 
and l igand f luorescence resonance 
energy transfer) have limitations in the 
assessment of heteromers due to poor 
signal-to-background ratio in human 
post-mortem brains (Fernandez-Duenas 
et al., 2019). Next, we demonstrated a 
functional interplay between the D2R 
and M1R in reserpinized mice, mimicking 
parkinsonian motor and non-motor 
impairments. Reserpine irreversibly 
blocks the vesicular  transporter of 
monoamines ,  which  resu l ts  in  the 
presynaptic depletion of monoamines 
(DA, serotonin and noradrenaline) and, 
thus, an increase in striatal ACh/DA ratio 
(McKinley et al., 2019). The reserpine-
induced  m o to r  d i st ur ba nce s  ( i . e . , 
akinesia, catalepsy and tremulous jaw 
movements) were significantly alleviated 
by multimodal treatment with an M1R-
selective antagonist (VU0255035) plus a 
D2R-selective agonist (sumanirole), both 
at suboptimal concentrations where 
these compounds were ineffective when 
administered as a stand-alone treatment 
(Crans et al., 2020). Noteworthy, we 
selected these compounds based on their 
high receptor subtype selectivity, where 
sumanirole is 200-fold more selective 
for D2R and VU0255035 has a 75-fold 
higher selectivity for M1R over other 
DARs and mAChRs, respectively (McCall 
et al., 2005; Sheffler et al., 2009). This 
goal-oriented strategy aimed to target 
putative D2R-M1R complexes located at 
striatopallidal neurons in reserpinized 
mice, where striatal DA is depleted by 
more than 90% (Figure 1B). Moreover, 
D2Rs are highly expressed at ChIs and 
their activation through sumanirole 
inhibits the release of ACh by ChIs. 
Although M4R antagonists have proven 
to alleviate parkinsonian motor deficits, 
however, selectively targeting M1Rs allows 
endogenously released ACh to activate 
M4Rs at ChIs, which may further reinstate 
the ACh/DA balance in reserpinized mice 
(Pisani et al., 2007; McKinley et al., 2019; 
Ztaou and Amalric, 2019). Nevertheless, 
pharmacotherapeutic usefulness of 
targeting D2R-M1R complexes should 
be validated in preclinical models of 
parkinsonism involving dopaminergic 
neurodegeneration, including toxic lesion 
(e.g., 6-hydroxydopamine) and genetic 
(e.g., Pitx3ak/ak) models of PD. 
Over  the last  decade,  the interest 
t o  m o d u l a t e  s t r i a t a l  f u n c t i o n  b y 
anticholinergic drugs has been renewed 
due to the development of improved 
pharmacological agents targeting specific 
mAChR subtypes (Sheffler et al., 2009; 
Ztaou and Amalric, 2019). Importantly, 
the pharmacological blockade of mAChR 
subtypes, more specifically M1R and M4R, 
have been demonstrated to alleviate 
ant ipark insonian def ic i ts ,  whereas 
treatment of wild-type mice with M1R-
selective agonist ( i .e. ,  telenzepine) 
reduced anxiety-like behaviors as well. 
Furthermore, M1R-deficient mice have 
an increased locomotor activity and 
elevated extracellular striatal DA levels, 
although these mice were not impaired 
in contextual fear condition, a test for 
hippocampus-dependent learning (Ztaou 
and Amalr ic ,  2019) .  The D 2R-MSNs 
are more efficiently suppressed than 
D1R-MSNs by M1R antagonists, which 
is suggested through their different 
subcellular expression of ion channels 
(e.g., potassium channels), regulated by 
M1Rs, that modulate the MSN excitatory 
synaptic input. In our perspective, the 
putative striatal D2R-M1R formation might 
result in further differentiation of M1R 
signalization between the striatopallidal 
and striatonigral neurons. For instance, 
due to a reciprocal antagonistic D2R-
M1R interaction, such as was previously 
described for the well-established D2R-
A2AR heteromer (Ferre et al.,  2018). 
Interestingly, the systemic administration 
of  scopolamine ( i .e . ,  non-select ive 
mAChR antagonist) and benztropine 
(i.e., moderate M1R-selective antagonist) 
reduced the affinity of raclopride and 
spiperone for D2R in monkey brains, 
respectively (Tsukada et al., 2000). These 
findings may emphasize a reciprocal 
interaction between D2Rs and M1Rs, 
although this needs to be further studied 
more in-depth. 
In summary, to restore the dopaminergic-
cholinergic imbalance, prevalent in 
most movement disorders, a novel and 
complementary pharmacotherapeutic 
approach based on a multimodal strategy 
using selective D2R agonist and M1R 
antagonist has been proposed. The 
use of suboptimal doses, which has no 
efficacy by itself, but with joint synergy 
as antiparkinsonians, will limit adverse 
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Figure 1 ｜ Schematic illustion of human basal ganglia circuitry and putative locations of neuronal DA 
and ACh receptors.
(A) The cortico-basal ganglia-thalamus circuit and striatal distribution of DA and ACh receptors at pre- 
and postsynaptic neurons. Schematic illustration (left) of the cortico-basal ganglia-thalamus circuit. DA-
projecting neurons from the SNc release DA in the caudate/putamen (i.e., neostriatum) to activate D1R-
MSNs of the direct pathway (blue lines) and inhibit D2R-MSNs of the indirect pathway (red lines). The 
basal ganglia output (GPi and SNr) descends their projections to the thalamus, which connects with 
the motor cortex. Simplified representation (right) of neurons and distribution of receptor subtypes 
within the striatum. The GABAergic interneuron (pink), ChI (orange), glutamatergic afferent (blue), 
DA-projecting neuron (green) and MSNs (yellow) express different mAChRs (M1R-M4R), nAChRs and 
DA receptor subtypes (D1R and D2R), emphasizing the complexity of the striatal circuitry. Multimodal 
strategy to alleviate parkinsonian symptoms in reserpinized mice. Reserpine depletes the DA levels 
within the striatum (left), resulting in a high striatal ACh/DA ratio and parkinsonian symptoms in mice. 
Our multimodal pharmacotherapy (right) with D2R agonist (sumanirole) and M1R antagonist (VU0255035) 
alleviated parkinsonian symptoms. While targeting the putative D2R-M1R heteromer, sumanirole also 
actives D2Rs at ChIs, thus contributing to the reinstatement of the ACh/DA ratio. A2AR: Adenosine A2A 
receptor; ACh: acetylcholine; ChIs: cholinergic interneurons; DA: dopamine; GABA: gamma-aminobutyric 
acid; GPe: globus pallidus pars externa; GPi: globus pallidus pars interna; mAChR: muscarinic 
acetylcholine receptor; MSN: medium spiny neuron; nAChR: nicotinic acetylcholine receptors; SNc: 
substantia nigra pars compacta; SNr: substantia nigra pars reticulata; STN: subthalamic nucleus.
effects (e.g., cognitive impairments) 
induced regularly by these dopaminergic 
and anticholinergic drugs used at optimal 
doses in PD treatment.
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